Answer
Satralizumab treatment should be delayed in patients with an active infection until it is controlled, including when a serious or opportunistic infection develops, when appropriate therapy should also be initiated under further monitoring.
Sources for this answer
- Enspryng 120 mg solution for injection in pre-filled syringeRoche Products Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked